Stefan Irion is the Chief Scientific Officer of GC Therapeutics, where he leads the scientific strategy behind a transcription-factor-based programming platform designed to generate functional cell therapies for ex vivo and in vivo delivery. The platform's combination of programmable cell identity and flexible delivery opens opportunities well beyond conventional cell replacement, positioning GCTx among the most credible paths from scientific possibility to broad patient access in next-generation cell therapy.

Prior to GCTx, Stefan spent nine years at BlueRock Therapeutics, where he held roles of increasing scope — Vice President of CNS, Senior Vice President of Research, and ultimately Chief Scientific Officer. There, he led cell therapy development through successive stages of clinical advancement, including the program that became bemdaneprocel, an investigational stem cell therapy for Parkinson's disease. Stefan had originally helped translate the underlying research findings at Memorial Sloan Kettering Cancer Center — where he served as Program Manager from 2013 to 2018 — into an IND and the formation of BlueRock. He then followed the work across two institutions and most of a decade, a continuity rare in translational medicine and central to advancing a research idea through manufacturing, regulatory, and scientific hurdles to patients.

Earlier in his biotech career, Stefan was Senior Scientist and Project Team Leader at iPierian, Inc., where he led the iPSC-based discovery work that produced IPN007, an anti-tau antibody for Alzheimer's disease that advanced into clinical development and contributed to the company's acquisition by Bristol-Myers Squibb. Before iPierian, he completed a postdoctoral fellowship at the University Health Network in Toronto, focused on cell biology, stem cell science, and gene targeting.

Stefan earned his M.D. at the University of Tübingen in Germany. His clinical training continues to anchor his approach to drug development — every program decision, in his view, ultimately traces back to a patient. Having built his career across three countries and multiple institutions, Stefan brings a conviction that the strongest scientific teams draw from genuinely diverse perspectives — scientifically, culturally, and operationally.